Drug Interactions and the Cytochrome P450 System: The Role of Cytochrome P450 1A2

Kim Brøsen*

*Kontaktforfatter for dette arbejde

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    Abstrakt

    Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content of human liver and is the major enzyme involved in the metabolism of imipramine, propranolol, clozapine, theophylline, and caffeine. It is also involved in the conversion of heterocyclic amines to their proximal carcinogenic and mutagenic forms, as well as in the metabolism of endogenous substances, including 17β-estradiol and uroporphyrinogen III. Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme. This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.

    OriginalsprogEngelsk
    TidsskriftClinical Pharmacokinetics
    Vol/bind29
    Udgave nummer1
    Sider (fra-til)20-25
    Antal sider6
    ISSN0312-5963
    DOI
    StatusUdgivet - 1. jan. 1995

    Fingeraftryk Dyk ned i forskningsemnerne om 'Drug Interactions and the Cytochrome P450 System: The Role of Cytochrome P450 1A2'. Sammen danner de et unikt fingeraftryk.

    Citationsformater